Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 54 points (0.3%) at 16,185 as of Wednesday, Feb. 19, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,812 issues advancing vs. 1,117 declining with 162 unchanged. The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.1%. A company within the industry that fell today was Grifols ( GRFS), up 1.4%. Top gainers within the industry include Forest Laboratories ( FRX), up 3.6%, Vertex Pharmaceuticals ( VRTX), up 2.7%, Shire ( SHPG), up 1.5% and Sanofi ( SNY), up 0.5%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Regeneron Pharmaceuticals is down $2.81 (-0.8%) to $329.97 on average volume. Thus far, 373,039 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 872,500 shares. The stock has ranged in price between $327.08-$331.74 after having opened the day at $328.86 as compared to the previous trading day's close of $332.78. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $31.7 billion and is part of the health care sector. Shares are up 20.9% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.